Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492335 | 0.85 | DHFR (0.54) | DHFRPTGDR2TMEM97SIGMAR1KDR | |
| SCHEMBL17868157 | 0.80 | BRD4 (0.65) | PTGDR2TMEM97SIGMAR1 | |
| SCHEMBL18926529 | 0.78 | PTGDR2 (0.42) | PTGDR2 | |
| SCHEMBL23706075 | 0.78 | DHFR (0.58) | DHFRTMEM97SIGMAR1KDR | |
| SCHEMBL16220576 | 0.75 | DHFR (0.53) | DHFRPTGDR2TMEM97SIGMAR1KDR | |
| SCHEMBL11402131 | 0.75 | BRD4 (0.45) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL22716563 | 0.74 | PTGDR2 (0.42) | DHFRPTGDR2TMEM97SIGMAR1KDR | |
| SCHEMBL17327930 | 0.74 | DHFR (0.52) | DHFRPTGDR2TMEM97SIGMAR1KDR | |
| SCHEMBL30902147 | 0.74 | PTGDR2 (0.51) | DHFRPTGDR2TMEM97SIGMAR1 | |
| SCHEMBL16210333 | 0.74 | TMEM97 (0.53) | DHFRPTGDR2TMEM97SIGMAR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | DHFR 256/4885PTGDR2 1720/4885TMEM97 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.